SPONSOR
Shenzhen Geno-Immune Medical Institute
Total Trials
6
Recruiting
6
Phases
Phase 1, Phase 1, Phase 2
Conditions studied: Multiple Myeloma or PlasmacytomaDiffuse Midline Glioma or Diffuse Intrinsic Pontine GliomaB-cell MalignanciesMelanomaAutoimmune DiseasesX-linked Adrenoleukodystrophy
Shenzhen Geno-Immune Medical Institute is a clinical research sponsor with 6 registered studies on ClinicalTrials.gov, of which 6 are actively recruiting participants. Research covers conditions including Multiple Myeloma or Plasmacytoma, Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, B-cell Malignancies, Melanoma.
The trial portfolio spans Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shenzhen Geno-Immune Medical Institute
How many clinical trials has Shenzhen Geno-Immune Medical Institute sponsored?
ClinicalMetric currently tracks 6 clinical trials sponsored by Shenzhen Geno-Immune Medical Institute, of which 6 are actively recruiting participants. These trials cover conditions including Multiple Myeloma or Plasmacytoma, Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, B-cell Malignancies. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shenzhen Geno-Immune Medical Institute research focus on?
Shenzhen Geno-Immune Medical Institute clinical trials span Multiple Myeloma or Plasmacytoma, Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, B-cell Malignancies, Melanoma, Autoimmune Diseases, and additional conditions. The research pipeline includes Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shenzhen Geno-Immune Medical Institute clinical trial?
To participate in a Shenzhen Geno-Immune Medical Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shenzhen Geno-Immune Medical Institute trials with current recruitment status updated daily.
Clinical Trials by Shenzhen Geno-Immune Medical Institute
NCT06435910 Phase 1
Recruiting
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Multiple Myeloma or Plasmacytoma
NCT07501156 Phase 1, Phase 2
Recruiting
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
NCT03125577 Phase 1, Phase 2
Recruiting
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
B-cell Malignancies
NCT07193966 Phase 1, Phase 2
Recruiting
NG2 and DLL3 CAR-T Cells Targeting Melanoma
Melanoma
NCT05459870 Phase 1, Phase 2
Recruiting
CAR-T Cells Targeting Autoimmune Diseases
Autoimmune Diseases
NCT03727555
Recruiting
IT and IV Lentiviral Gene Therapy for X-ALD
X-linked Adrenoleukodystrophy
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology